BARBOLINI, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.890
EU - Europa 2.445
AS - Asia 2.363
SA - Sud America 356
Continente sconosciuto - Info sul continente non disponibili 74
AF - Africa 59
OC - Oceania 13
Totale 10.200
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.706
IT - Italia 810
SG - Singapore 703
CN - Cina 543
GB - Regno Unito 372
IE - Irlanda 316
VN - Vietnam 249
BR - Brasile 240
HK - Hong Kong 235
DE - Germania 190
BD - Bangladesh 188
SE - Svezia 149
FI - Finlandia 117
FR - Francia 112
RU - Federazione Russa 96
CA - Canada 91
IN - India 67
ID - Indonesia 64
KR - Corea 53
TR - Turchia 49
JP - Giappone 40
UA - Ucraina 38
AR - Argentina 37
NL - Olanda 33
BE - Belgio 29
LT - Lituania 26
MX - Messico 26
BG - Bulgaria 25
CO - Colombia 25
PL - Polonia 24
ES - Italia 22
MY - Malesia 20
TW - Taiwan 19
IQ - Iraq 18
VE - Venezuela 16
CL - Cile 14
CZ - Repubblica Ceca 14
EC - Ecuador 14
IR - Iran 13
AT - Austria 12
SA - Arabia Saudita 12
ZA - Sudafrica 12
AE - Emirati Arabi Uniti 11
AU - Australia 11
CR - Costa Rica 11
AL - Albania 10
EU - Europa 9
MA - Marocco 9
PK - Pakistan 9
PR - Porto Rico 8
TT - Trinidad e Tobago 8
UZ - Uzbekistan 8
GP - Guadalupe 7
IL - Israele 7
JM - Giamaica 7
TH - Thailandia 7
CW - ???statistics.table.value.countryCode.CW??? 6
DK - Danimarca 6
EG - Egitto 6
HN - Honduras 6
KE - Kenya 6
NP - Nepal 6
RS - Serbia 6
GT - Guatemala 5
MT - Malta 5
OM - Oman 5
PH - Filippine 5
RO - Romania 5
SV - El Salvador 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
GR - Grecia 4
JO - Giordania 4
NI - Nicaragua 4
PT - Portogallo 4
SC - Seychelles 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
BH - Bahrain 3
HR - Croazia 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NO - Norvegia 3
PE - Perù 3
PY - Paraguay 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
AM - Armenia 2
BO - Bolivia 2
CI - Costa d'Avorio 2
GA - Gabon 2
LV - Lettonia 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
QA - Qatar 2
SI - Slovenia 2
UY - Uruguay 2
Totale 10.124
Salva come PNG Salva come JPEG
Città #
Ashburn 689
Singapore 445
Santa Clara 427
San Jose 356
Dublin 314
Chandler 310
Hong Kong 223
Fairfield 219
Council Bluffs 215
Dallas 163
Southend 150
Hefei 142
Beijing 120
Woodbridge 113
Nyköping 112
New York 109
Helsinki 104
Seattle 100
Ann Arbor 99
London 92
Houston 90
Wilmington 90
Los Angeles 86
Ho Chi Minh City 82
Modena 79
Cambridge 72
The Dalles 64
Hanoi 62
Milan 60
Dearborn 59
Seoul 52
Jakarta 45
Lauterbourg 45
Rome 45
Bologna 41
Chicago 40
Jacksonville 40
Munich 40
Moscow 37
Shanghai 35
Fremont 34
São Paulo 30
San Diego 28
Redwood City 27
Buffalo 26
Toronto 25
Columbus 24
Orem 24
Sofia 24
Tokyo 24
Princeton 23
Brussels 22
Frankfurt am Main 21
San Giuliano Milanese 19
Paris 18
Parma 18
Phoenix 18
Reggio Emilia 18
Bremen 17
Denver 17
Dong Ket 17
Warsaw 17
Brooklyn 16
Montreal 16
Eugene 15
Redondo Beach 15
Falls Church 14
Florence 14
Mumbai 14
North Bergen 14
Portsmouth 14
Boardman 13
Düsseldorf 11
Guangzhou 11
Haiphong 11
Naples 11
New Taipei 11
Genoa 10
Izmir 10
Nuremberg 10
Springfield 10
Atlanta 9
Charlotte 9
Chennai 9
Poplar 9
Salt Lake City 9
Baghdad 8
Bari 8
Brno 8
Caprarola 8
Cardiff 8
Da Nang 8
Glasgow 8
Kent 8
Mexico City 8
Newark 8
Quito 8
San José 8
Stockholm 8
Tashkent 8
Totale 6.554
Salva come PNG Salva come JPEG
Nome #
GD2 expression in breast cancer. 449
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 427
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 419
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 407
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 405
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 390
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 384
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 380
The evolving role of microsatellite instability in colorectal cancer: A review 376
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 371
A concise review of lenalidomide therapy for follicular lymphoma 367
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 348
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 344
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 339
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 337
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 317
Breast Location for De Novo Extramedullary Myeloid Sarcoma 312
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 306
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 297
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 296
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 291
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 283
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 274
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 264
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 256
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 243
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 241
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 228
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 222
LETTER TO THE EDITOR: Henoch-schönlein Purpura (HSP) in a Patient on Abemaciclib 214
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 184
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 180
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments. 49
Totale 10.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.448
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.448
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022447 0 0 0 0 27 55 31 38 58 43 113 82
2022/20231.154 84 128 89 80 82 91 26 84 367 32 46 45
2023/2024648 31 35 62 65 61 57 78 62 35 36 64 62
2024/20251.718 58 35 61 119 325 239 131 108 188 106 140 208
2025/20263.705 238 98 317 331 447 219 528 198 359 363 280 327
2026/2027994 113 191 267 351 72 0 0 0 0 0 0 0
Totale 10.200